Elutia (ELUT) Asset Writedowns and Impairment (2023 - 2024)

Elutia (ELUT) reported Asset Writedowns and Impairment of $209000.0 for Q4 2024, up 185.66% sequentially from -$244000.0 in Q3 2023.

Elutia (ELUT) Asset Writedowns and Impairment (2023 - 2024) Analysis & Trends

Elutia (ELUT) has 2 years of Asset Writedowns and Impairment data on file, last reported at $209000.0 in Q4 2024.

For the quarter ending Q4 2024, Asset Writedowns and Impairment changed N/A year-over-year to $209000.0; the trailing twelve-month figure through Dec 2024 stood at -$35000.0 (changed N/A YoY), and the FY2025 full-year result was $458000.0, changed 0.43% from the prior year.
Asset Writedowns and Impairment climbed to $209000.0 in Q4 2024, from -$244000.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $209000.0 in Q4 2024 to a low of -$244000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	181.39 Bn	174.10 Bn	6.27 Bn
2	Stryker	128.38 Bn	125.50 Bn	3.81 Bn
3	Medtronic	107.68 Bn	98.46 Bn	6.41 Bn
4	Boston Scientific	67.98 Bn	66.53 Bn	3.61 Bn
5	Edwards Lifesciences	47.81 Bn	44.13 Bn	1.29 Bn
6	GE HealthCare Technologies	28.53 Bn	26.25 Bn	1.98 Bn
7	Dexcom	28.35 Bn	27.24 Bn	750.30 Mn
8	Smith & Nephew	26.78 Bn	26.20 Bn	-
9	Koninklijke Philips	25.34 Bn	22.21 Bn	2.07 Bn
10	Elutia	40.85 Mn	12.36 Mn	1.80 Mn

Download Data